Goldman Sachs analyst Corinne Johnson initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Early-Stage Biotech rating.The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE